Company research
CEL SCI CORP
CIK 725363Updated Sep 24, 2026
SecurityCVM · NYSE_AMERICAN · equity
Historical securities (1)
CVM.WS · NYSE_AMERICAN · warrant · closed Oct 9, 2018CVM price & chart
Loading TradingView…
AMEX:CVM on TradingView ↗About the company
We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
ARS filing
DEF 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 28,155,748Source | 26,991,766Source | 30,528,250Source | 50,523,706Source |
| Property, Plant and Equipment, NetUSD | 6,079,295Source | 8,129,753Source | 10,188,126Source | 11,889,029Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 22,672,138Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 0Source |
| Inventory, NetUSD | — | 1,019,908Source | 2,248,072Source | 2,001,715Source |
| Assets, CurrentUSD | 11,596,128Source | 6,055,678Source | 6,918,420Source | 25,435,916Source |
| Operating Lease, Right-of-Use AssetUSD | 1,274,780Source | 1,495,937Source | 1,698,243Source | 1,884,464Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,198,663Source | 14,124,683Source | 17,313,360Source | 18,360,499Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 80,157Source | 637,870Source | 474,223Source | 434,484Source |
| Additional Paid in CapitalUSD | 555,299,844Source | 526,241,074Source | 499,832,063Source | 486,625,816Source |
| Retained Earnings (Accumulated Deficit)USD | -539,422,916Source | -514,011,861Source | -487,091,396Source | -454,897,093Source |
| Stockholders' Equity Attributable to ParentUSD | 15,957,085Source | 12,867,083Source | 13,214,890Source | 32,163,207Source |
| Liabilities and EquityUSD | 28,155,748Source | 26,991,766Source | 30,528,250Source | 50,523,706Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,130,546Source | 4,615,779Source | 5,585,846Source | 4,663,751Source |
| Operating Lease, Liability, CurrentUSD | 166,990Source | 226,969Source | 197,431Source | — |
| Accounts Payable, CurrentUSD | 1,061,351Source | 1,448,467Source | 2,009,786Source | 1,618,290Source |
| Operating Lease, Liability, NoncurrentUSD | 1,258,990Source | 1,425,979Source | 1,652,949Source | 1,850,380Source |
| Other Liabilities, NoncurrentUSD | 125,000Source | 125,000Source | 125,000Source | 125,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 711,820Source | 566,042Source | 1,049,581Source | 842,492Source |
| Deferred Tax Liabilities, NetUSD | 1,615,000Source | 2,095,000Source | 2,713,000Source | 3,288,000Source |
| Short-term InvestmentsUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 25,411,000Source | -26,920,465Source | -32,194,303Source | 36,700,681Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,056,000Source | 2,135,000Source | 2,114,000Source | 1,977,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,910,997Source | 4,270,180Source | 6,286,231Source | 11,389,932Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | — | 172,608Source | -156,727Source | 159,430Source |
| Increase (Decrease) in Accounts PayableUSD | -442,710Source | -460,576Source | 257,845Source | 374,890Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -17,119,737Source | -18,811,206Source | -22,848,561Source | -18,240,951Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -38,109Source | -108,086Source | -372,262Source | 5,491,367Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 38,109Source | 94,875Source | 361,892Source | 637,892Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 23,373,133Source | 19,511,730Source | 4,694,420Source | -638,426Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,953,460Source | 4,738,173Source | 4,145,735Source | 22,672,138Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 768,466Source | 923,807Source | 1,062,564Source | 1,157,069Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 27,000Source | 32,000Source | — | 30,793Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 0Source | 366,791Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | 615Source |
| General and Administrative ExpenseUSD | 8,922,759Source | 8,191,023Source | 9,004,578Source | 10,707,447Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -25,411,055Source | -27,579,921Source | -32,194,303Source | -36,700,681Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,411,055Source | — | -32,365,855Source | -37,629,803Source |
| Operating ExpensesUSD | 24,809,736Source | 26,352,474Source | 31,476,074Source | 36,062,793Source |
| Other Nonoperating Income (Expense)USD | 47,625Source | 177,682Source | -42,813Source | 107,148Source |
| Proceeds from Issuance of Common StockUSD | 28,291,100Source | 23,575,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | 0Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 6,000Source | 6,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -24,809,736Source | -26,352,474Source | -31,476,074Source | -36,062,793Source |
| Other Nonoperating Income (Expense)USD | 47,625Source | 177,682Source | -42,813Source | 107,148Source |
| Net Income (Loss) Attributable to ParentUSD | -25,411,055Source | -27,579,921Source | -32,194,303Source | -36,700,681Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.87Source |
| Earnings Per Share, DilutedUSD per share | -6.27Source | -0.51Source | — | -0.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 43,148,888Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,055,738Source | 54,044,989Source | — | 43,148,888Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 27,000Source | 32,000Source | — | 30,793Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,885,153Source | 3,969,183Source | 3,958,334Source | 3,828,917Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | 615Source |
| General and Administrative ExpenseUSD | 8,922,759Source | 8,191,023Source | 9,004,578Source | 10,707,447Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.87Source |
| Interest ExpenseUSD | 649,000Source | 745,673Source | 675,416Source | — |
| Interest Income (Expense), NetUSD | -648,944Source | — | — | -1,081,034Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,411,055Source | — | -32,365,855Source | -37,629,803Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | — | -37,629,803Source |
| Operating ExpensesUSD | 24,809,736Source | 26,352,474Source | 31,476,074Source | 36,062,793Source |
| Other IncomeUSD | 48,000Source | — | — | — |
| Research and Development ExpenseUSD | 15,886,977Source | 18,161,451Source | 22,471,496Source | 25,355,346Source |
Offerings
Registration 333-295168
- Gross proceeds
- 7200000.0
- Net proceeds
- 6696000.0
- Deal price
- 1.2
- Shares
- 6000000
- Offering price
- $1.20
- Ticker
- CVM
Filing attachments
cvm_ex991.htm · 8-K · 2026-06-16
EX-99.1 4 cvm_ex991.htm PRESS RELEASE DATED JUNE 14, 2026 cvm_ex991.htm EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PRICING OF OFFERING Vienna, VA, June 14, 2026 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immun…
Read attachment ↗cvm_ex992.htm · 8-K · 2026-06-16
EX-99.2 5 cvm_ex992.htm PRESS RELEASE DATED JUNE 16, 2026 cvm_ex992.htm EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF OFFERING Vienna, Virginia - June 16, 2026 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunother…
Read attachment ↗cvm_ex991.htm · 8-K · 2026-05-13
EX-99.1 2 cvm_ex991.htm PRESS RELEASE cvm_ex991.htm EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, Va. 22182 USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Corporation Announces Pricing of Public Offering Vienna, VA, May 11, 2026 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public of…
Read attachment ↗cvm_ex992.htm · 8-K · 2026-05-13
EX-99.2 3 cvm_ex992.htm PRESS RELEASE cvm_ex992.htm EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, Virginia - May 13, 2026 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, t…
Read attachment ↗cvm_ex991.htm · 8-K · 2025-08-29
EX-99.1 4 cvm_ex991.htm PRESS RELEASE cvm_ex991.htm EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia - August 27, 2025 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer i…
Read attachment ↗cvm_ex992.htm · 8-K · 2025-08-29
EX-99.2 5 cvm_ex992.htm PRESS RELEASE cvm_ex992.htm EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: ──────────────────────────────────────────────────────────── Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia - August 29, 2025 - CEL-SCI Corporation (“CEL-SCI” o…
Read attachment ↗